Company Overview and News
In the week that ended on April 13, 2018, crude oil (USO) prices rose significantly from $62.06 per barrel to $67.39 per barrel, a rise of almost 9%. Crude oil prices saw a very strong positive trend within the week, rising on all five days.
TOTAL S.A. (TOT - Free Report) made full utilization of its financial strength to acquire several assets in the Gulf of Mexico (GOM) region from the Cobalt International Energy’s bankruptcy auction sale. TOTAL made an offer of $300 million to acquire 20% interest in the North Platte discovery, 20% stake in Anchor discovery and operation rights in 13 offshore exploration blocks. The U.S. Bankruptcy Court has approved the above transfer of rights to TOTAL on Apr 5, 2018.
Future Market Insights assesses the shale gas hydraulic fracturing market in the U.S, Canada, and China in its newly published report titled, “Shale Gas Hydraulic Fracturing Market: Canada, US, and China Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027.” According to the report, the US market production value is anticipated to expand from 18,059 BCF (2017) at a 9.8% CAGR, Canadian market's production volume of 213.
I have been a staunch proponent and unit holder of Viper Energy Partners (VNOM) since late 2015. I think they have been and currently are the best defensive play in the American Energy space. Many investors are turned off by variable rate distribution schemes. Not me. I am a firm believer in paying out what you can when you can. On the business end, no borrowing to cover an unsustainable dividend. On the investor side, no analysis of fuzzy metrics like payout ratios.
Devon Energy Corporation (DVN - Free Report) decided to reduce its current workforce by 9% or 300 workers with an objective to streamline its operations, improve returns and boost margins, per a media report. The layoffs will begin in the next few weeks and impact all areas of the company’s operations, including its headquarters. Devon Energy expects the decision to cut down its existing workforce to result in savings within $150-$200 million in 2020.
Over the last three years, the energy market has experienced intense price volatility. However, it seems that following an extended period of relative weakness, energy stocks are finally on their way to recovery. With crude now firmly back over $60, the panic that swept over the market are all but gone. The incredible turnaround has stoked high expectations from the energy sector going into the first quarter of 2018.
HOUSTON (Reuters) - Devon Energy Corp said on Tuesday it would lay off 300 workers, roughly 9 percent of staff, part of a plan to streamline operations and boost the shale oil producer’s sagging returns and stock price.
HOUSTON, April 10 (Reuters) - U.S. shale oil producer Devon Energy Corp said on Tuesday it would lay off 300 workers, roughly 9 percent of staff, part of a plan to streamline its operations.
Natural Gas Liquids (NGLs) Industry report offers a comprehensive insight into the development policies and plans in addition to manufacturing processes and cost structures. On the basis of product, this report displays the Cost Structure, Sales Revenue, Sales Volume, Gross Margin, market share and growth rate.
Last week, crude oil (USO) prices decreased significantly from $64.94 per barrel to $62.06 per barrel, a fall of more than 4%. This fall was the second consecutive weekly loss for crude oil prices. Crude oil prices saw a negative trend within the week, falling considerably on Monday and Friday.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET